GlassScriptPhysician profile
Annette M Bernard
NPI 1831232024
$8,934.73
in general payments reported to CMS, 2019-2025
43 companies · $1,720 in 2025
The $1,720 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $1,031 · 2021: $1,188 · 2022: $826 · 2023: $1,386 · 2024: $1,751 · 2025: $1,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,857.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,765.13 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $1,560.14 | 2019-2025 | Biktarvy |
| Lilly USA, LLC | $767.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $629.57 | 2019-2025 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $568.04 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Novo Nordisk INC | $531.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Theratechnologies INC. | $387.30 | 2019-2025 | Egrifta, Trogarzo |
| Abbvie INC. | $316.52 | 2020-2025 | Ubrelvy |
| Janssen Biotech, INC. | $314.95 | 2019-2023 | Symtuza |
| Napo Pharmaceuticals INC | $238.05 | 2019-2025 | Mytesi |
| Pfizer INC. | $154.80 | 2019-2024 | |
| Emd Serono, INC. | $151.04 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $116.38 | 2019-2022 | |
| Esperion Therapeutics, INC. | $113.56 | 2021-2025 | Nexletol |
| Glaxosmithkline, LLC. | $109.36 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $100.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $95.58 | 2023-2025 | Veozah |
| Paratek Pharmaceuticals, INC. | $87.54 | 2021-2023 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $85.58 | 2019-2024 | Airsupra |
| Biohaven Pharmaceuticals, INC. | $79.67 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $66.99 | 2019-2022 | |
| Dexcom, INC. | $60.44 | 2021-2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $49.17 | 2019-2023 | Aptima |
| Madrigal Pharmaceuticals | $48.32 | 2025 | Rezdiffra |
| Amarin Pharma, INC. | $47.01 | 2019-2020 | |
| Allergan, INC. | $45.86 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $41.60 | 2022-2023 | Quviviq |
| Abbott Laboratories | $38.63 | 2022-2025 | Freestyle Libre 3 |
| Tolmar, INC. | $36.08 | 2023-2025 | Jatenzo |
| Radius Health, INC. | $33.78 | 2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $32.46 | 2025 | |
| Janssen Pharmaceuticals, INC | $31.00 | 2019 | |
| Lundbeck LLC | $30.44 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $26.95 | 2025 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $24.83 | 2023 | |
| Acerus Pharmaceuticals Corporation | $24.38 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.18 | 2020 | |
| Antares Pharma, INC. | $20.77 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.14 | 2025 | Jardiance |
| Sequel Med Tech, LLC | $17.02 | 2025 | Twiist |
| Philips North America LLC | $16.22 | 2024 | (Ck7) Extended Holter |
| Eisai INC. | $15.86 | 2021 | |
| Ethicon US, LLC | $15.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Bernard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.